Victus has been sold to Megalabs
Headquartered in Miami, Victus, Inc. is a global leader in clinical nutrition, needle-free connectology, infusion, critical care systems and advanced wound care. All the company’s products are developed and refined using medical professional and patient feedback, and its Enterex brand of nutritional supplements has become one of the most trusted and recognizable names in the industry. Victus generates sales in more than 25 countries and more than 28,000 retail locations across all of North, Central and South America.
In 2020, the company launched multiple strategic, management-led initiatives that delivered meaningful, permanent margin improvement. In 2021, Victus saw significant geographic expansion in both new and existing territories, driving strong revenue growth. Given the company’s new financial profile, management began considering options to best support the company’s strong growth trajectory. In late-2021, the shareholders engaged Lincoln International to execute a bespoke sale process to identify a new partner to support the company’s next phase.
Roddy O’Neill, Managing Director and Co-Head of Lincoln’s U.S. Healthcare Group, commented, “We are grateful to have had the opportunity to work with such an innovative company like Victus. Management has built a tremendous platform, and we look forward to tracking the company’s continued growth with its new partner, Megalabs.”
Meet our Senior Team
View More Transactions in Healthcare and Consumer
Lincoln International advised Aquiline Capital Partners on the acquisition of Health Prime from GPB Capital Holdings
Lincoln International advised Talisman Capital Partners on the sale of ADVOCATE RCM to Ventra Health, a portfolio company of Varsity Healthcare Partners
Lincoln International advised Mars on the sale of Diamond Animal Health to Veterinary Pharmaceutical Solutions, a portfolio company of Granite Creek Capital Partners
Lincoln International advised 7Mind on its sale to Gymondo, a portfolio company of Oakley Capital
Lincoln International advised 22nd Century Group on the sale of GVB Biopharma to Specialty Acquisition Corporation
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.